» Articles » PMID: 39636695

Variation in HIV-1 Tat Activity is a Key Determinant in the Establishment of Latent Infection

Overview
Journal JCI Insight
Date 2024 Dec 5
PMID 39636695
Authors
Affiliations
Soon will be listed here.
Abstract

Despite effective treatment, human immunodeficiency virus (HIV) persists in optimally treated people as a transcriptionally silent provirus. Latently infected cells evade the immune system and the harmful effects of the virus, thereby creating a long-lasting reservoir of HIV. To gain a deeper insight into the molecular mechanisms of HIV latency establishment, we constructed a series of HIV-1 fluorescent reporter viruses that distinguish active versus latent infection. We unexpectedly observed that the proportion of active to latent infection depended on a limiting viral factor, which created a bottleneck that could be overcome by superinfection of the cell, T cell activation, or overexpression of HIV-1 transactivator of transcription (Tat). In addition, we found that tat and regulator of expression of virion proteins (Rev) expression levels varied among HIV molecular clones and that tat levels were an important variable in latency establishment. Lower rev levels limited viral protein expression whereas lower Tat levels or mutation of the Tat binding element promoted latent infection that was resistant to reactivation even in fully activated primary T cells. Nevertheless, we found that combinations of latency reversal agents targeting both cellular activation and histone acetylation pathways overcame deficiencies in the Tat/TAR axis of transcription regulation. These results provide additional insight into the mechanisms of latency establishment and inform Tat-centered approaches to cure HIV.

References
1.
Hashemi F, Barreto K, Bernhard W, Hashemi P, Lomness A, Sadowski I . HIV Provirus Stably Reproduces Parental Latent and Induced Transcription Phenotypes Regardless of the Chromosomal Integration Site. J Virol. 2016; 90(11):5302-14. PMC: 4934743. DOI: 10.1128/JVI.02842-15. View

2.
Raines S, Falcinelli S, Peterson J, Van Gulck E, Allard B, Kirchherr J . Nanoparticle delivery of Tat synergizes with classical latency reversal agents to express HIV antigen targets. Antimicrob Agents Chemother. 2024; 68(7):e0020124. PMC: 11232404. DOI: 10.1128/aac.00201-24. View

3.
Van Gulck E, Pardons M, Nijs E, Verheyen N, Dockx K, Van Den Eynde C . A truncated HIV Tat demonstrates potent and specific latency reversal activity. Antimicrob Agents Chemother. 2023; 67(11):e0041723. PMC: 10649039. DOI: 10.1128/aac.00417-23. View

4.
Levy D, Refaeli Y, MacGregor R, Weiner D . Serum Vpr regulates productive infection and latency of human immunodeficiency virus type 1. Proc Natl Acad Sci U S A. 1994; 91(23):10873-7. PMC: 45128. DOI: 10.1073/pnas.91.23.10873. View

5.
Agbottah E, Deng L, Dannenberg L, Pumfery A, Kashanchi F . Effect of SWI/SNF chromatin remodeling complex on HIV-1 Tat activated transcription. Retrovirology. 2006; 3:48. PMC: 1570494. DOI: 10.1186/1742-4690-3-48. View